Chapter 27  Bradycardia

Panos E. Vardas, Hercules E. Mavrakis, and William D. Toff

References


The World Survey

86  Da Costa A, Kirkorian G, Cucherat M,
83  Cazeau S, Ritter P, Bakdach S,
84  Bernstein AD, Camm AJ, Fletcher RD,
79  Mond HG, Irwin M, Ector H, Proclemer A. The World Survey
78  Furman S, Robinson G. The use of an intracardiac pacemaker
77  Elmqvist R, Senning A, Smyth CN (eds.). Medical Electronics:
69  Horowitz LN, Kay HR, Kutalek SP, et al. Risks and
68  Rajappan K. Permanent pacemaker implantation technique:
65  Aggarwal RK, Connelly DT, Ray SG, et al. Early complications
63  Hoffman JR. Emergency department management of life-
61  Antell HI, Mond HG, Irwin M, Ector H, Proclemer A. The World Survey
60  Vagnini FJ, Gourin A, Antell HI, Mond HG, Irwin M, Ector H, Proclemer A. The World Survey
35  Andersen HR, Nielsen JC, Thomsen PE, et al. Arterial thromboembolism in patients with sick sinus syndrome:
prediction from pacing mode, atrial fibrillation, and echocardiographic findings. Heart 1999; 81: 412–18.


127 Andersen HR, Swendsen JH. The Danish multicenter randomized study on atrial inhibited versus dual-chamber pacing in sick sinus syndrome (the DANPACE study). Heart Drug 2001; 1: 67–70.


134 Funck RC, Boriani G, Manolis AS, et al. The MINERVA study design and rationale: A controlled randomized trial to
assess the clinical benefit of minimizing ventricular pacing in pacemaker patients with atrial tachyarrhythmias. *Am Heart J* 2008; **156**: 445–51.


© 2009 The European Society of Cardiology

© 2009 The European Society of Cardiology